Taro Pharmaceutical Industries AFFILIATED WEBSITES CONTACT ABOUT US WORLDWIDE SITES RESEARCH INVESTOR RELATIONS GROWTH THROUGH RESEARCH Taro's investments in research have enabled it to become a U.S. leader in topical prescription products (creams, ointments and gels). Approximately 1 in 8 tubes of such products sold in the U.S. READ MORE ABOUT TARO RESEARCH & DEVELOPMENT TARO PRODUCTS INVESTOR RELATIONS Taro is a research-based international pharmaceutical company that was established on the principal that research and development would be the cornerstone of its growth strategy. Providing quality products through scientific innovations, diligence and precision is the goal of all of Taro's research programs. Taro develops high-quality, proprietary and off-patent pharmaceuticals for markets in the US, Canada, Israel and other countries around the world... READ MORE PRESS RELEASES 01 DEC Taro Appoints New Chief Financial Officer 28 OCT Taro Provides Results for September 30, 2021 21 OCT Taro to Announce Second Quarter Results on October 28, 2021 READ MORE Copyright © Taro Pharmaceutical Industries Ltd. Privacy Statement | Terms of Use | Safe Harbor Statement Sitemap | Site Credits

Skip to main navigation Investor Relations Investor Relations Stock Information Fundamentals Earnings Release and Call Transcripts Annual Reports & Latest Proxy News Releases Analysts Investor Presentation SEC Filings Event Calendar Board of Directors Investor FAQ E-mail Alerts Contact Information Safe Harbor Home Page Investor Relations Corporate Profile Welcome to Taro’s Investor Relations Website Established in 1950, Taro Pharmaceutical Industries Ltd. is a multinational science-based pharmaceutical company that develops, manufactures and markets generic and branded prescription and over-the-counter (OTC) pharmaceutical products. Taro’s research programs and niche strategy have enabled the Company to achieve leadership in dermatological products in the United States. Business Overview Taro develops, manufactures and markets prescription and OTC pharmaceutical products primarily in the United States, Canada and Israel. Taro’s primary areas of focus include pediatric creams and ointments, liquids, capsules and tablets, mainly for the dermatological, topical, cardiovascular, neuropsychiatric and anti-inflammatory therapeutic categories. 2021 - AGM Proxy Card (common stock) Exchange (US Dollar) Price Change (%) () Volume Data as of 12/03/21 8:49 AM EST Click Here for Stock Quote Data on NYSE More >> Recent News Date Title Additional Formats Toggle Summary 12/01/21 Taro Appoints New Chief Financial Officer View HTML Toggle Summary 10/28/21 Taro Provides Results for September 30, 2021 View HTML Toggle Summary 10/21/21 Taro to Announce Second Quarter Results on October 28, 2021 View HTML Data Provided by Refinitiv. Minimum 15 minutes delayed. 2000-2007 Taro Pharmaceutical Industries Ltd. All Rights Reserved Terms of Use | Privacy Statement | Safe Harbor Statement